Table 2 Clinical trials: Registered MSC-based treatment in ARDS

NCT01775774 (Completed)

ARDS

1

BM-MSCs

1, 5, 10 × 10⁶ cells/kg

I.V

Infusion associated adverse events

NCT02097641 (Completed)

ARDS

2a

BM-MSCs

1 × 10⁷ cells/kg

I.V

Infusion associated adverse events, numbers of death within 24 h

NCT01902082 (Unknown)

ARDS

1

AD-MSCs

1 × 10⁶ cells/kg

I.V

Adverse events

NCT02804945 (Completed)

ARDS in patients with malignancies

1

BM-MSCs

3 × 10⁶ cells/kg

I.V

Adverse events

ChiCTR2000029990 (Recruiting)

Covid-19-related pneumonitis

1–2

BM-MSCs

1 × 10⁶ cells/kg

I.V

Blood oxygen saturation

NCT04355728 (Recruiting)

Covid-19 patients

1–2

UC-MSCs

1 × 10⁸ cells

(2 times)

I.V

Adverse events

NCT03042143 (Recruiting)

Covid-19-related ARDS

1–2

UC-MSCs

1, 2, 4 × 10⁸ cells

I.V

Oxygenation index, adverse events

NCT04390139 (Recruiting)

Covid-19-related respiratory distress

1–2

WJ-MSCs

1 × 10⁶ cells/kg

I.V

All-cause mortality at day 28

NCT02095444 (Recruiting)

H7N9-related ARDS

1–2

MB-MSCs

1 × 10⁷ cells/kg (4 times)

I.V

The degree of lung injury within 14 days

NCT04416139 (Recruiting)

Covid-19-related ARDS

2

UC-MSCs

1 × 10⁶ cells/kg

I.V

PaO2/FiO2 ratio, heart rate, respiratory rate, changes in body temperature

NCT04366063 (Recruiting)

Covid-19-related ARDS

2–3

BM-MSCs

1 × 10⁸ cells (2 times)

I.V

Adverse events, blood oxygen saturation

NCT04371393 (Recruiting)

Covid-19-related ARDS

3

BM-MSCs

2 × 10⁶ cells/kg (2 times)

I.V

All-cause mortality at day 30